Xoma Fails Phase 3 Trial For Rare Eye Disease
July 22, 2015 at 20:29 PM EDT
Xoma shares closed the day down 77% after failing a phase 3 trial for Behcets-disease Uveitis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.